Advances in antiviral drug discovery and development: Part I: Advancements in antiviral drug discovery

Future Virology

Volumn 4, Issue 2, 2009, Pages 101-107

  Saxena, Shailendra K ^a   Mishra, Niraj ^a   Saxena, Rakhi ^a  

^a CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; MICRORNA; PROTEINASE INHIBITOR; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; SMALL INTERFERING RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CROSS RESISTANCE; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; VIRUS LATENCY; VIRUS REPLICATION;

EID: 70349206194     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.4.2.101     Document Type: Editorial

References (35)

1. Abe M, Kaneko K, Ueda A et al.: Effects of several virucidal agents on inactivation of influenza, Newcastle disease, and avian infectious bronchitis viruses in the allantoic fluid of chicken eggs. Jpn. J. Infect. Dis. 60, 342-346 (2007).
2. Irving W, Boswell T, Ala'Aldeen D: Medical Microbiology. Taylor & Francis Publication, PA, USA (2005).
3. Patric G: Medicinal Chemistry. BIOS Scientific Publisher, Oxford, UK (2002).
4. Bean B: Antiviral therapy: current concepts and practices. Cli. Miicrobiol. 5, 146-182 (1992).
5. Field HJ: Antiviral chenristry 8c cheotherapy's current antiviral agents FactFile (2nd Edition). Ativir. Chem. Chemother. 19(2), 49-50 (2008).
6. Weller IV, Williams IG: ABC of AIDS. Antiretroviral drugs. BMJ 322, 1410-1412 (2001).
7. Rowley M: The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog. Med. Chem. 46, 1-28 (2008).
8. Wang Z, Vince R: Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. Bioorg. Med. Chem. 16, 3587-3595 (2008).
9. De Clercq E: Antiviral drugs in current clinical use. J. Clin. Virol. 30, 115-133 (2004).
10. Saxena SK, Mathur A, Srivastava RC: Inhibition of Japanese encephalitis virus infection by diethyldithiocarbamate is independent of its antioxidant potential. Antivir. Chem. Chemother. 14, 91-98 (2003).
11. De Clercq E, Neyts J: Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends. Pharmacol. Sci. 28, 280-285 (2007).
12. Kleymann G: Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir. Chem. Chemother. 15, 135-140 (2004).
13. Chan SS, Santos JH, Meyer JN et al.: Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or ZT/3TC in combination. Environ. Mol. Mutagen. 48, 190-200 (2007).
14. Robinson B, Li Z, Nath A: Nucleoside reverse transcriptase inhibitors and human immunodeficiency virus proteins cause axonal injury in human dorsal root ganglia cultures. J. Neurovirol. 13, 160-167 (2007).
15. Venholf N, Setzer B, Melkaoui K et al.: Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir. Ther. 12, 1075-1085 (2007).
16. Margot NA, Waters JM, Miller MD: In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob. Agents Chemother. 50, 4087-4095 (2006).
17. Murphy M, Monteiro E: Acyclovir-resistant herpes simplex virus infection in HIV-infected patients: a report of three cases and a review of management. J. Europ. Acad. Dermatol. Venereol. 2, 322-327 (2006).
18. Delaugerre C, Wirden M, Simon A et al.: Resistance profile and cross-resistance to HIV-1 among 104 patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. Presented at: The 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, 8 August 2001 (Abstract).
19. Jeffrey S, Baker D, Tritch R et al.: A resistance and cross resistance profile for SUSTIVA (efavirenz, DMP 266). Presented at: The 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA, 5 August 1998 (Abstract).
20. Kumar A: RNA interference: a multifaceted innate antiviral defense. Retrovirolqgy5, 17 (2008).
21. Reyes-Darias JA, Sánchez-Luque FJ, Berzal-Herranz A: Inhibition of HIV-1 replication by RNA-based strategies. Curr. HIV Res. 6, 500-514 (2008).
22. Kanda T, Steele R, Ray R et al.: Small interfering RNA targeted to hepatitis C virus 5′ nontranslated region exerts potent antiviral effect. J. Virol. 81, 669-676 (2007).
23. Gitlin L, Stone JK, Andino R: Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J. Virol. 79, 1027-1035 (2005).
24. Lecellier CH, Dunoyer P, Arar K et al.: A cellular microRNA mediates antiviral defense in human cells. Science 308, 557-560 (2005).
25. Scaria V, Hariharan M, Maid S K et al.: Host-virus interaction: a new role for microRNAs. Retrovirology 3, 68 (2006).
26. Butz K, Denk C, Fitscher B et al. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20, 6579-6586 (2001).
27. Hwang B, Cho JS, Yeo HJ et al. Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus. RNA 10, 1277-1290 (2004).
28. Crawford M, Woodman R, Ko Ferrigno P: Peptide aptamers: tools for biology and drug discovery. Brief Funct. Genomic. Proteomic. 2, 72-79 (2003).
29. Zu Putlitz J, Yu Q, Burke JM et al: Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus. J. Virol. 73, 5381-5387 (1999).
30. Nazari R, Ma XZ, Joshi S: Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA. J. Gen. Virol. 89, 2252-2261 (2008).
31. Welch PJ, Yei S, Barber JR: Ribozyme gene therapy for hepatitis C virus infection. Clin. Diagn. Virol. 10, 163-171 (1998).
32. Peracchi A: Prospects for antiviral ribozymes and deoxyribozymes. Rev. Med. Virol. 14, 47-64 (2004).
33. Hillaireau H, Le Doan T, Appel M: Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J. Control. Release 116, 346-352 (2006).
34. Rossi L, Brandi G, Schiavano GF et al.: Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. AIDS Res. Hum. Retroviruses 15, 345-353 (1999).
35. Patel D, Sawant KK: Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev. Ind. Pharm. 33, 1318-1326 (2007).